> **Galenica again achieves strong sales growth - Galenica.com**

> Galenica Group sales performed well in 2023, growing by 4.4% to CHF 3,746.0 million. As expected, sales growth of 3.

- Language: en
- Last Modified: 2026-11-20
- Source: <https://www.galenica.com/en/storyhub/eqs/51a894be-e51f-4eb7-91ed-5dd7f67b9ec5.php>
- Alternate (fr): <https://www.galenica.com/fr/storyhub/eqs/51a894be-e51f-4eb7-91ed-5dd7f67b9ec5.php>
- Alternate (de): <https://www.galenica.com/de/storyhub/eqs/51a894be-e51f-4eb7-91ed-5dd7f67b9ec5.php>
- Search: <https://www.galenica.com/en/search/index.php?searchTerm={search_term_string}>

---

Ad hoc announcement pursuant to Art. 53 LR  2024/01/18

# Galenica again achieves strong sales growth

**Galenica Group sales performed well in 2023, growing by 4.4% to CHF 3,746.0 million. As expected, sales growth of 3.3% in the second half of 2023 was lower than the +5.5% recorded in the first half due to the exceptionally strong comparative period in the second half of 2022, when there was a strong seasonal flu epidemic and COVID-19 infections.**

**In particular, the “Logistics & IT” segment posted strong growth of 4.9%. The “Products & Care” segment also performed well with sales growth of 3.3%, supported by the strong performance of 12.3% of the “Products & Brands” sector. **

**The strong performance of the overall pharmaceutical market, with growth of 4.9%, particularly contributed to the sales growth. This development was driven by increased sales of high-priced medications, with sales volumes declining by 0.2%. **

### Earnings outlook confirmed

**Galenica confirms its guidance for the 2023 financial year, with EBIT1  at roughly the same level as the previous year2, and the outlook for the 2023 dividend at least at the same level as the previous year.**

**Net sales of the Galenica Group 2023:**

| (in million CHF) | 2023 | 20222 | Change |
| --- | --- | --- | --- |
| Products & Care segment | 1,635.6 | 1,584.0 | +3.3% |
| Retail (B2C) | 1,385.6 | 1,360.7 | +1.8% |
| Local Pharmacies | 1,306.9 | 1,286.9 | +1.6% |
| Pharmacies at Home | 78.9 | 74.0 | +6.6% |
| Professionals (B2B) | 256.1 | 228.8 | +11.9% |
| Products & Brands | 177.1 | 157.7 | +12.3% |
| Services for Professionals | 78.9 | 71.1 | +11.0% |
| Logistics & IT segment | 3,077.0 | 2,933.3 | +4.9% |
| Wholesale | 2,952.7 | 2,820.4 | +4.7% |
| Logistics & IT Services | 144.0 | 130.7 | +10.1% |
| Corporate and eliminations | -966.6 | -928.8 |  |
| Galenica Group | 3,746.0 | 3,588.5 | +4.4% |

1 Excluding the effects of IFRS 16 and IAS 19

2  Adjusted prior-year figures due to joint venture with Redcare Pharmacy (formerly Shop Apotheke Europe)

### “PRODUCTS & CARE” SEGMENT

The “Products & Care” segment achieved net sales of CHF 1,635.6 million (+3.3%) in financial year 2023. The Retail business area (B2C) accounted for CHF 1,385.6 million (+1.8%), with the “Local Pharmacies” sector contributing CHF 1,306.9 million (+1.6% excluding Coop Vitality) and the “Pharmacies at Home” sector CHF 78.9 million (+6.6%, without Mediservice). Adjusted for the extraordinary additional sales in connection with COVID-19 the previous year, sales growth for “Local Pharmacies” amounted to +2.7%.

The “Professionals” (B2B) business area increased sales to CHF 256.1 million (+11.9%), with the “Products & Brands” sector contributing CHF 177.1 million (+12.3%) and the “Services for Professionals” sector contributing CHF 78.9 million (+11.0%).

### “Retail” business area (B2C)

- The 2.7% growth of "Local Pharmacies" adjusted for COVID-19 is in line with the market trend.
- As expected, sales growth in the second half of 2023 was lower than in the first half due to the exceptionally strong comparative period in the second half of 2022, when there was a strong seasonal flu epidemic and COVID-19 infections.
- Compared to the previous year, demand for vaccinations in Galenica pharmacies increased by 18% (without COVID-19 vaccinations).
- Around 138,000 customers made use of the health services and advice offered by Galenica pharmacies in 2023, 14% more than in the previous year.
- Together with Redcare Pharmacy, Galenica established Switzerland’s leading online pharmacy, adding a pure online pharmacy to its offering.

**By way of comparison: **

- Drug sales from bricks-and-mortar pharmacies in Switzerland (prescription [Rx] and OTC products) grew by 4.4% in the reporting year (IQVIA, Pharmaceutical Market Switzerland, 2023).
- Sales of medications from mail-order pharmacies in Switzerland (prescription [Rx] and OTC products) grew by 1.7% in the reporting year (IQVIA, Pharmaceutical Market Switzerland, 2023).
- The non-medication segment of the consumer healthcare market declined by 1.3% in the reporting year (IQVIA, Consumer Health Market Switzerland, 2023, Nutrition, Personal Care, Patient Care, excluding COVID-19 self-tests, excluding OTC).

### “Professionals” business area (B2B)

- With the acquisition of Padma, Verfora further expanded its complementary medicine offering, increasing its market share in the Swiss consumer healthcare market to 10.3%.
- Verfora’s export sales showed very positive growth, with an increase of 33.6%. This pleasing result was driven by a recovery in demand for products such as travel and cold products, among other things, as well as the expansion of storage capacity abroad, for Perskindol® for instance, due to a regulatory change that will soon come into effect.
- The Galenica network’s home care services performed very successfully, with growth well above the previous year.

**By way of comparison: **

- The consumer healthcare market grew by 0.7% year-on-year (IQVIA, Consumer Health Market Switzerland, 2023, excluding COVID-19 self-tests).

### “LOGISTICS & IT” SEGMENT

The “Logistics & IT” segment achieved net sales of CHF 3,077.0 million (+4.9%) in the 2023 financial year. CHF 2,952.7 million (+4.7%) of this was generated by the “Wholesale” sector and CHF 144.0 million (+10.1%) by the “Logistics & IT Services” sector.

### “Wholesale” sector

- The pharmacy customer segment recorded growth of 5.4%. Adjusted for additional sales related to COVID-19, which were still high in the previous year, sales growth amounted to 6.3%. Further market share was gained with third-party pharmacies.
- The physicians segment also did well in the year, growing 3.6%.
- With the “Safety Stock” initiative Galexis is actively committed to improving the security of supply in Switzerland.

**By way of comparison: **

- The overall pharmaceutical market grew by 4.9% (IQVIA, Pharmaceutical Market Switzerland, 2023).
- The physicians segment grew by 7.8% (IQVIA, Pharmaceutical Market Switzerland, 2023).
- The pharmacy segment grew by 4.1% (IQVIA, Pharmaceutical Market Switzerland, 2023).

### “Logistics & IT Services” sector

- In addition to its robust basic business, Alloga was able to take over distribution from a leading manufacturer of vaccines.
- The Documedis® physicians and pharmacy software continued to develop technically in the year under review. In 2023, over 270 million “Clinical Decision Support Checks” (CDS) were carried out on the basis of Documedis® solutions.

Additional information on sales figures and further information can be found in our [investor presentation](https://www.galenica.com/galenica23Assets/bin/en/corporate-information/sales-update-jan-24.pdf).

[Sales 2023 of the Galenica Group](https://eqs-cockpit.com/c/fncls.ssp?u=69561c66b4d255ef9e9aa987c96877d6&inline_display=1)

Share post:

[back](https://www.galenica.com/de/news/entries/2024-10-22-partnerschaft-stapferhaus.php)

## Media inquiries & contact

Do you have questions about Galenica?
Get in touch with us.

[Media inquiries & contact](https://www.galenica.com/en/medien-news/medienkontakte.php)

## You might also be interested in this

Press releases

2026/11/18

#### Verfora acquires majority stake in distribution partner Qpharma

With Qpharma, Verfora is gaining an established Polish pharmaceutical distributor with a strong distribution platform in Central and Eastern Europe.

[Verfora acquires majority stake in distribution partner Qpharma](https://www.galenica.com/en/storyhub/eqs/86792312-b676-44cf-85a8-3274a5ad078e.php)

Press releases

2026/10/26

#### Galenica successfully places a bond of over CHF 200 million

Today, Galenica successfully placed a fixed rate bond of over CHF 200 million. The bond has a term of 4 years and an annual coupon of 1.2775%.

[Galenica successfully places a bond of over CHF 200 million](https://www.galenica.com/en/storyhub/eqs/216bfdff-51da-47a5-b9fd-a0fb4222acf2.php)

Ad hoc announcements

2026/10/22

#### Galenica continues growth trajectory and confirms outlook for 2026

Galenica increases sales by 5.7% to CHF 3,172.0 million in the first nine months of 2026. The pharmacy business and home care are key contributors to growth.

[Galenica continues growth trajectory and confirms outlook for 2026](https://www.galenica.com/en/storyhub/eqs/75d2d9ff-4b40-4a24-8f9a-71d7d8e85670.php)

2026/09/17

#### Five football pitches full of medication – and one system for emergencies

Millions of packs of medicines are stored in Burgdorf. Some of them are intended for the moment when the market can no longer guarantee supply. How this compulsory stock works and is drawn upon, why it is far from being a dusty emergency reserve, and what role the Galenica network company Alloga plays in supplying Switzerland.

[Five football pitches full of medication – and one system for emergencies](https://www.galenica.com/en/news/entries/20260915-6827872869-news.php)

2026/09/01

#### A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge

The long-established Bären Apotheke am Zytglogge has been part of Bern’s cityscape for generations. Since 1 September 2026, it has been part of the Galenica network and continues to operate under the name “Bären Vita Zytglogge” with a new concept. This preserves a piece of Bern’s history while opening up new prospects for its future.

[A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge](https://www.galenica.com/en/news/entries/20260831-1530729059-news.php)

2026/08/31

#### Creating New Spaces in Harmony with Our Culture

The world of work is constantly evolving, and Galenica is evolving with it. As part of our transformation, we are actively shaping the future. This is reflected not only in the way we collaborate, but also in the environments in which we work.

[Creating New Spaces in Harmony with Our Culture](https://www.galenica.com/en/news/entries/20260828-4185621035-news.php)

Ad hoc announcements

2026/08/06

#### Galenica maintains its track record of consistent growth

Galenica increases sales by 7.1% to CHF 2,136.5 million in the first half of 2026. Adjusted<sup>1</sup> EBIT increases by 7.1% to CHF 117.7 million.

[Galenica maintains its track record of consistent growth](https://www.galenica.com/en/storyhub/eqs/56b03300-1d96-40ad-8ba5-2aa0e5bb109b.php)

2026/06/30

#### Change in the Executive Committee of Labor Team

Alain M. Cahen will step down as CEO of Labor Team at the end of June 2026 and will also leave the Executive Committee. COO Thomas Brinkmann will take over on an interim basis.

[Change in the Executive Committee of Labor Team](https://www.galenica.com/en/news/entries/20260630-1601920926-news.php)

Video

2026/06/18

#### Coordinated basic care: From pilot projects to system solutions

Collaboration between different healthcare providers is already being tested in numerous pilot projects. One recent example is the Baselland supply model, which also involves participation from pharmacies in the Galenica network. The task going forward is to develop these approaches systematically and translate them into sustainable, broad-based system solutions. Daniele Madonna, Chief Pharmacies Category Management & Health Services, called for this step at this year’s Healthcare Professionals Initiative on 5 June 2026.

[Coordinated basic care: From pilot projects to system solutions](https://www.galenica.com/en/news/entries/20260617-4349880772-news.php)

Video

2026/06/01

#### Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept

With the redesigned Sun Store pharmacy in Renens (VD), the first pharmacy in Western Switzerland is opening with a completely new concept. It places a strong focus on personalised advice, healthcare services and the overall customer experience. The aim is to further improve people’s access to low-threshold primary care services.

[Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept](https://www.galenica.com/en/news/entries/20260428-7147085906-news.php)